tm
Seeing Is Believing
tm
Seeing Is Believing
FDMT is currently covered by 9 analysts with an average price target of $30.03. This is a potential upside of $25.9 (627.12%) from yesterday's end of day stock price of $4.13.
4D Molecular Therapeutics 's activity chart (see below) currently has 25 price targets and 58 ratings on display. The stock rating distribution of FDMT is 92.5% BUY, 2.5% HOLD and 5% SELL.
Analysts average stock forecasts to be materialized ratio is 33.27% with an average time for these price targets to be met of 98.33 days.
Highest price target for FDMT is $44, Lowest price target is $6, average price target is $32.71.
Most recent stock forecast was given by SALVEEN RICHTER from GOLDMAN SACHS on 09-May-2025. First documented stock forecast 05-Jan-2021.
Currently out of the existing stock ratings of FDMT, 37 are a BUY (92.5%), 1 are a HOLD (2.5%), 2 are a SELL (5%).
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$44
$39.87 (965.38%)
1 months 12 days ago
(09-May-2025)
0/3 (0%)
$40.92 (1328.57%)
Buy
$40
$35.87 (868.52%)
3 months 11 days ago
(10-Mar-2025)
1/2 (50%)
$36.1 (925.64%)
243
Buy
$28
$23.87 (577.97%)
3 months 17 days ago
(04-Mar-2025)
3/6 (50%)
$24.03 (605.29%)
201
Buy
$36
$31.87 (771.67%)
3 months 18 days ago
(03-Mar-2025)
0/15 (0%)
$31.47 (694.70%)
Buy
$35
$30.87 (747.46%)
$39
3 months 18 days ago
(03-Mar-2025)
2/7 (28.57%)
$30.47 (672.63%)
29
What is FDMT (4D Molecular Therapeutics ) average time for price targets to be met?
Which analyst has the current highest performing score on FDMT (4D Molecular Therapeutics ) with a proven track record?
Which analyst has the current lower performing score on FDMT (4D Molecular Therapeutics ) with a proven track record?
Which analyst has the most public recommendations on FDMT (4D Molecular Therapeutics )?
Which analyst is the currently most bullish on FDMT (4D Molecular Therapeutics )?
Which analyst is the currently most reserved on FDMT (4D Molecular Therapeutics )?
